Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.
Combination therapy with subcutaneous peginterferon alpha-2a (40KD) [Pegasys] plus oral ribavirin (Copegus) has been evaluated previously in patients with chronic hepatitis C and elevated ALT levels. A recent randomised, nonblind, multicentre trial examined the efficacy of this combination therapy in the treatment of patients with persistently 'normal' ALT levels. These trial results showed that combination therapy with peginterferon alpha-2a (40KD) plus ribavirin is effective in patients with chronic hepatitis C and persistently normal ALT levels. Overall, a sustained virological response occurred in over 50% of patients who received combination therapy for 48 weeks, albeit with a low daily dosage of ribavirin. The tolerability profile of combination therapy in patients with persistently normal ALT levels is similar to that seen in patients with elevated ALT levels. The decision as to whether or not treatment should be initiated in patients with chronic hepatitis C and persistently normal ALT levels should be made on an individual basis. If a decision is made to treat, combination therapy with peginterferon alpha-2a (40KD) plus ribavirin can be considered a first-line treatment option.
Keating
Gillian M
GM
Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz
Plosker
Greg L
GL
D000410:Alanine Transaminase / Q000378:metabolism; D000998:Antiviral Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000494:pharmacology*; D011788:Quality of Life; D011994:Recombinant Proteins; D012254:Ribavirin / Q000494:pharmacology*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000410:Alanine Transaminase; C100416:peginterferon alfa-2a
Hepatology. 1998 Mar;27(3):868-72
9500720
Am J Gastroenterol. 2004 Sep;99(9):1706-7
15330906
Drugs. 2001;61(15):2263-88
11772139
Hepatology. 2004 Apr;39(4):1147-71
15057920
Ann Intern Med. 2004 Mar 2;140(5):346-55
14996676
Hepatology. 1997 Aug;26(2):473-7
9252161
J Hepatol. 2003 Apr;38(4):511-7
12663245
Gastroenterology. 2004 May;126(5):1409-15
15131801
Gastroenterology. 2004 Mar;126(3):703-14
14988824
BMJ. 2004 Apr 24;328(7446):983
15028636
Hepatology. 1992 Sep;16(3):649-54
1505907
J Med Virol. 2003 Jan;69(1):50-8
12436477
Br J Clin Pharmacol. 2000 May;49(5):417-21
10792198
NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46
14768714
Expert Opin Pharmacother. 2003 Apr;4(4):541-51
12667117
Hepatology. 2004 Dec;40(6):1442-9
15565603
Hepatology. 1997 Sep;26(3 Suppl 1):133S-136S
9305678
BMJ. 2001 Nov 17;323(7322):1141-2
11711386
Hepatology. 2002 Nov;36(5 Suppl 1):S179-84
12407592
N Engl J Med. 2001 Jul 5;345(1):41-52
11439948
J Hepatol. 1996 Nov;25(5):591-8
8938532
J Hepatol. 1999;31 Suppl 1:9-16
10622554
Rev Infect Dis. 1990 Nov-Dec;12(6):1139-46
2267489
J Immunol. 1998 Apr 1;160(7):3487-93
9531310
J Med Virol. 1993 Oct;41(2):99-102
8283183
Pharmacol Ther. 1979;6(1):123-46
390559
Gastroenterology. 2002 Oct;123(4):1070-83
12360469
Ann Intern Med. 2002 Jul 2;137(1):1-10
12093239
Drugs. 2003;63(7):701-30
12656650
Gastroenterology. 2004 Dec;127(6):1724-32
15578510
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
J Gen Virol. 1998 Oct;79 ( Pt 10):2381-91
9780043
Ann Intern Med. 2002 Dec 17;137(12):961-4
12484711
J Hepatol. 1999 Mar;30(3):376-82
10190717
Hepatology. 2002 Oct;36(4 Pt 1):973-7
12297846